Matches in Wikidata for { <http://www.wikidata.org/entity/Q59888167> ?p ?o ?g. }
- Q59888167 description "article scientifique publié en 2017" @default.
- Q59888167 description "article" @default.
- Q59888167 description "im Juli 2017 veröffentlicher wissenschaftlicher Artikel" @default.
- Q59888167 description "wetenschappelijk artikel" @default.
- Q59888167 description "наукова стаття, опублікована в липні 2017" @default.
- Q59888167 name "Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, c" @default.
- Q59888167 name "Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, c" @default.
- Q59888167 type Item @default.
- Q59888167 label "Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, c" @default.
- Q59888167 label "Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, c" @default.
- Q59888167 prefLabel "Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, c" @default.
- Q59888167 prefLabel "Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, c" @default.
- Q59888167 P1154 Q59888167-A4415452-8FDA-4C37-9727-5B1BF952BA9F @default.
- Q59888167 P1433 Q59888167-C253D08D-C80B-4074-8BA8-A5678B7BCE38 @default.
- Q59888167 P1476 Q59888167-8EE98393-4281-4098-BA5F-74622F9566AA @default.
- Q59888167 P2093 Q59888167-0AEDF8EF-D5E4-49D2-88B8-39E9FEC8C397 @default.
- Q59888167 P2093 Q59888167-265DB74B-55FD-402C-AA73-36E33711FF9D @default.
- Q59888167 P2093 Q59888167-3EAAFDC9-79D6-4C1F-A6C4-2F39680CECAC @default.
- Q59888167 P2093 Q59888167-48D7D7D3-7767-475E-88E4-5AD57B43B93B @default.
- Q59888167 P2093 Q59888167-5698D21A-CE23-4F91-8A77-68332FC642E0 @default.
- Q59888167 P2093 Q59888167-58FE13C2-C7D4-4FAF-AF76-01E8E6A3538C @default.
- Q59888167 P2093 Q59888167-70EC8AFD-12FA-4EA9-9A91-75F5E45B8180 @default.
- Q59888167 P2093 Q59888167-71E873F6-A9FF-4AFC-8186-E29C430394DD @default.
- Q59888167 P2093 Q59888167-7B74924A-547F-4815-A5CE-8BDF350830F4 @default.
- Q59888167 P2093 Q59888167-8498ED44-2A94-4025-BBF3-F525BDF9BD5C @default.
- Q59888167 P2093 Q59888167-92B29473-2D0B-454D-AF0E-CA1ED0EE6E96 @default.
- Q59888167 P2093 Q59888167-96F16CB4-A99F-47C5-98CE-AC71BAB1ECFC @default.
- Q59888167 P2093 Q59888167-98676DC6-D29F-4319-BB18-CE988928692A @default.
- Q59888167 P2093 Q59888167-B48CA6C9-2EEC-4CB6-BA49-DAE1DEAEF2B5 @default.
- Q59888167 P2093 Q59888167-BC7F4A6D-E10A-4030-A1C1-7573725AC3D0 @default.
- Q59888167 P2093 Q59888167-F1F8483D-B3CE-441B-A217-C77B83A9EC0B @default.
- Q59888167 P2093 Q59888167-F4EBAC4B-CD5A-4CE5-8FC1-3AAB6395D84F @default.
- Q59888167 P2093 Q59888167-F787FB01-E04B-4D59-88EA-EA3CE6476A2D @default.
- Q59888167 P2860 Q59888167-1136EA76-F8F4-4543-9219-2BF68E867389 @default.
- Q59888167 P2860 Q59888167-1699DB3F-D9A9-4C5C-A3FB-54178F8B1699 @default.
- Q59888167 P2860 Q59888167-2602CCE5-6CE8-4AA2-894C-9B22AF3DE074 @default.
- Q59888167 P2860 Q59888167-2C50A342-C91C-4FA0-8138-50105890B11C @default.
- Q59888167 P2860 Q59888167-2EC017E2-FE7F-4F96-A9BE-3AB569D90FAE @default.
- Q59888167 P2860 Q59888167-32E0A9B2-8372-490F-9836-71E7429123E9 @default.
- Q59888167 P2860 Q59888167-4486ECA5-6439-4768-B181-EC50CFEE1F99 @default.
- Q59888167 P2860 Q59888167-803D96C6-2956-4184-A5CA-200E6AD2C326 @default.
- Q59888167 P2860 Q59888167-88212C9A-BC82-4D85-9564-97605F679E70 @default.
- Q59888167 P2860 Q59888167-8A13101C-8D6D-4BF6-8DE1-536D9C9DB102 @default.
- Q59888167 P2860 Q59888167-8A974361-6135-4EF0-8A68-27BFBA1E9403 @default.
- Q59888167 P2860 Q59888167-8D166450-8848-4859-836E-FBB668190477 @default.
- Q59888167 P2860 Q59888167-8D3DBAD8-7D1D-48AE-911D-E726A5A33B8C @default.
- Q59888167 P2860 Q59888167-99977C4C-6DA2-4524-845A-D65CFD69A88B @default.
- Q59888167 P2860 Q59888167-A138C039-53F8-4765-AEA8-8E1A45788078 @default.
- Q59888167 P2860 Q59888167-A8B2F214-0232-4495-851D-13C9F3A2D804 @default.
- Q59888167 P2860 Q59888167-ADB97EFD-B536-4DCD-9286-6797113CAC66 @default.
- Q59888167 P2860 Q59888167-C1A88C5D-0D05-46DA-9B15-463207DB30C7 @default.
- Q59888167 P2860 Q59888167-D706B005-8BFC-409B-8587-E1C595D4F9AD @default.
- Q59888167 P2860 Q59888167-D850FB37-207D-43F8-9C8E-2D70E3A6BE76 @default.
- Q59888167 P2860 Q59888167-DBB24202-A2ED-4CEA-8085-751A8A96F69D @default.
- Q59888167 P2860 Q59888167-DBBE5D8E-4D8B-455E-A534-43C68400B36A @default.
- Q59888167 P2860 Q59888167-F8F5C318-4AD5-488F-B86A-E0C78FB76221 @default.
- Q59888167 P304 Q59888167-56AD831C-CE86-4A96-97A2-60A4571D0E04 @default.
- Q59888167 P31 Q59888167-B7C3DDBB-37C3-4DE9-9324-B730DEA1AE8D @default.
- Q59888167 P356 Q59888167-75931EE1-3C03-488F-B9F8-AAE454E98D72 @default.
- Q59888167 P407 Q59888167-5848A099-DAEF-469C-A9C4-B7172B0549A2 @default.
- Q59888167 P433 Q59888167-B4936B4B-823F-4573-BCB7-DDE2D683C1AB @default.
- Q59888167 P478 Q59888167-F162983C-178D-4022-971A-67B80622145D @default.
- Q59888167 P50 Q59888167-0B705438-F3CA-4786-A401-354FF6C3D11F @default.
- Q59888167 P50 Q59888167-36AF926F-CDDD-4CF1-855F-09B801E02382 @default.
- Q59888167 P50 Q59888167-5258D19F-E1BD-4E82-9947-EAE648C61D96 @default.
- Q59888167 P50 Q59888167-7298132F-81E7-4165-9C77-630CB6D12938 @default.
- Q59888167 P50 Q59888167-A425E175-79BF-4E6B-8BAC-E966202D69B0 @default.
- Q59888167 P50 Q59888167-DC3276AC-9BEB-4D39-8387-228ABF2595D4 @default.
- Q59888167 P5530 Q59888167-3CCFFFBC-79BF-4435-BE21-F62512AC227F @default.
- Q59888167 P577 Q59888167-6FB53A07-8F65-424C-AC0C-D5BE5D0AFFA4 @default.
- Q59888167 P6179 Q59888167-CCEC2E37-1420-4CC1-BC03-324B2FCBC32A @default.
- Q59888167 P6366 Q59888167-9C22B27A-58B8-4843-96C1-AA5FE5FD6A35 @default.
- Q59888167 P698 Q59888167-D2171697-23A4-43A1-8C85-CA91A9DDA833 @default.
- Q59888167 P921 Q59888167-DA7F7AFE-C8D0-4696-B97F-F531875251DA @default.
- Q59888167 P921 Q59888167-EF0C757B-7822-49D7-BCD1-308D60FA6158 @default.
- Q59888167 P921 Q59888167-F2A85E83-5DB5-4C94-A28E-555AAE183CEA @default.
- Q59888167 P921 Q59888167-F3AD612C-C68C-48C4-855B-CC07CFF1770E @default.
- Q59888167 P921 Q59888167-FE8E090B-AFC3-4B08-BBB1-A2A00EF3B38A @default.
- Q59888167 P932 Q59888167-BD080F12-7755-4B3B-AFCB-784F777607DE @default.
- Q59888167 P953 Q59888167-0A9311A9-3AD3-4C45-A435-9A70A3B771D1 @default.
- Q59888167 P356 S1470-2045(17)30404-7 @default.
- Q59888167 P6366 2621656000 @default.
- Q59888167 P698 28600210 @default.
- Q59888167 P1154 "2-s2.0-85020458396" @default.
- Q59888167 P1433 Q13747613 @default.
- Q59888167 P1476 "Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, c" @default.
- Q59888167 P2093 "A Murray Brunt" @default.
- Q59888167 P2093 "Alexa Gillman" @default.
- Q59888167 P2093 "Claire Gaunt" @default.
- Q59888167 P2093 "David Bloomfield" @default.
- Q59888167 P2093 "David Cameron" @default.
- Q59888167 P2093 "Gianfilippo Bertelli" @default.
- Q59888167 P2093 "Jane Banerji" @default.
- Q59888167 P2093 "John Bartlett" @default.
- Q59888167 P2093 "Mark Verrill" @default.
- Q59888167 P2093 "Nicholas Hearfield" @default.
- Q59888167 P2093 "Nicholas Murray" @default.
- Q59888167 P2093 "Niki Couper" @default.
- Q59888167 P2093 "Paul Ellis" @default.
- Q59888167 P2093 "Peter Barrett-Lee" @default.